Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Villejuif
Clinical trial register · France

Clinical Trials in Villejuif, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9731 matching records held by the registry are in this view. Synced 02 Nov 2026, 03:18 UTC
9731
Studies in scope
all four open statuses
6052
Recruiting now
open to new participants
1028
Lead sponsors
across recruiting studies
Top sites
Paris 64 Bordeaux 62 Montpellier 61 Lyon 60 Marseille 58
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris59 AstraZeneca33 Merck Sharp & Dohme LLC22 GlaxoSmithKline21 Bristol-Myers Squibb21 Clear sponsor filter
Site location
Paris64 Bordeaux62 Montpellier61 Lyon60 Marseille58
All 106 locations
Target enrolment
to

Trials with a site in Villejuif

33 of 9731 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
AstraZeneca
Phase 3
670
Villejuif
2026-05-04
Recruiting
AstraZeneca
Phase 3
2,130
Bordeaux, Caen, Lyon, Marseille, Rennes, Villejuif
2026-02-03
Recruiting
AstraZeneca
Phase 1/2
283
Lyon, Montpellier, Saint-Herblain, Suresnes, Villejuif
2025-10-01
Active, closed
AstraZeneca
Phase 2
82
Montpellier, Poitiers, Saint-Priez En Jarez, Villejuif
2025-03-12
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Clermont-Ferrand, Montpellier, Paris, Saint-Cloud, Villejuif
2025-01-30
Recruiting
AstraZeneca
Phase 1/2
174
Pessac, Villejuif
2024-09-18
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
Créteil, Dijon, Lille, Pierre-Bénite, Villejuif
2024-01-23
Recruiting
AstraZeneca
Phase 1/2
334
Villejuif
2024-01-18
Recruiting
AstraZeneca
Phase 3
1,145
Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif
2023-12-14
Active, closed
AstraZeneca
Phase 3
760
Marseille, Montpellier, Pessac, Rennes, Strasbourg, Toulouse, Villejuif
2023-12-04
Recruiting
AstraZeneca
Phase 3
625
Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif
2023-11-23
Active, closed
AstraZeneca
Phase 3
142
Clichy, Dijon, Montpellier, Villejuif
2023-08-16
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Toulouse, Villejuif
2023-07-11
Active, closed
AstraZeneca
Phase 3
37
Villejuif
2023-05-08
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Marseille, Rennes, Villejuif
2022-12-21
Active, closed
AstraZeneca
Phase 3
148
Bordeaux, Quimper, Toulouse, Villejuif
2021-10-28
Active, closed
AstraZeneca
Phase 3
454
Bordeaux, Dijon, Le Mans, Lyon, Marseille, Nantes, Toulouse, Villejuif
2021-10-28
Active, closed
AstraZeneca
Phase 3
732
Bezannes, Bordeaux, Lille, Lyon, Montpellier, Plérin, Toulouse, Villejuif
2021-10-18
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
DrugSabestomig
AstraZeneca
Phase 1/2
136
Bordeaux, Rennes, Villejuif
2021-09-28
Active, closed
AstraZeneca
Phase 3
893
Bobigny, Limoges, Lyon, Plérin, Rouen, Saint-Herblain, Villejuif
2021-05-10
Recruiting
AstraZeneca
Phase 1
304
Bordeaux, Dijon, Pierre-Bénite, Saint-Herblain, Villejuif
2021-03-09
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
Bordeaux, Lyon, Villejuif
2020-12-30
Active, closed
AstraZeneca
Phase 1/2
245
Villejuif
2020-12-28
Active, closed
AstraZeneca
Phase 1
138
Villejuif
2020-12-17
Active, closed
AstraZeneca
Phase 3
640
Besançon, Lille, Lyon, Montpellier, Reims, Rouen, Strasbourg, Villejuif
2020-10-19
Active, closed
AstraZeneca
Phase 3
185
Lille, Lyon, Plérin, Villejuif
2020-08-04
Active, closed
AstraZeneca
Phase 3
587
Bordeaux, Lyon, Montpellier, Villejuif
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Brest, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain, Villejuif
2019-06-25
Active, closed
AstraZeneca
Phase 3
724
Bron, Dijon, Lyon, Nantes, Pierre-Bénite, Toulouse, Villejuif
2019-03-06
Active, closed
AstraZeneca
Phase 2
528
Bordeaux, Nantes, Paris, Villejuif
2017-12-18
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
DrugsSavolitinib·Sunitinib
AstraZeneca
Phase 3
60
Bordeaux, Vandœuvre-lès-Nancy, Villejuif
2017-07-25
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bordeaux, Lyon, Saint-Herblain, Villejuif
2014-10-31
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Bordeaux, Caen, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy, Villejuif
2013-08-26
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 November 2026. https://priyalifescience.com/clinical-trials-france/city/villejuif

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,731 studies in total at the last sync on 02 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Villejuif that also match the filters currently applied.

How many clinical trials are recruiting in Villejuif?

11 of the 33 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 22 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Villejuif), 33 studies
PhaseStudiesRecruitingShare
Phase 318454.5%
Phase 1/28624.2%
Phase 14112.1%
Phase 2309.1%

Most active sponsors

Lead sponsors with the most studies (Villejuif)
Lead sponsorStudiesRecruiting
AstraZeneca3311
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.